Oryn is a clinical stage biotechnology company developing a portfolio of revolutionary bio-inspired Orynotides as therapeutics for autoimmune and chronic inflammatory diseases, infectious diseases, and oncology. Orynotides are highly stable cyclic peptides with demonstrated preclinical efficacy in models of each of the listed disease categories, and are both non-toxic and non-immunogenic. The following chart summarizes Oryn's current product pipeline and program development efforts:
Oryn’s lead candidate ORTD-1 is a macrocyclic peptide with demonstrated anti-inflammatory properties. ORTD-1 was initially developed as a subcutaneous injection for the treatment of rheumatoid arthritis (RA). A Phase 1a study was completed in healthy volunteers demonstrating the safety of subcutaneous ORTD-1, and a Phase 1b study in RA patients is currently in progress.
Additionally, Oryn has begun a Phase 1b/2 study evaluating intravenous ORTD-1 for the treatment of SARS-CoV-2–related pneumonia (COVID-19).
Oryn is actively pursuing applications of Orynotides for additional infectious and chronic inflammatory diseases, as well as certain cancers.